For nearly 30 years, Myoderm has been a specialist in global clinical trial supply, with deep expertise in sourcing, management, and labeling of commercial drugs and supplies. Our ingenuity, strategic thinking, and obsession with providing the most efficient, effective, and seamless supply solutions is why top pharmaceutical companies, biotech companies, CROs, and clinical trial packagers around the world rely on Myoderm for their supply needs. With headquarters in Europe and North America, and an extensive global network of manufacturers and suppliers, we pride ourselves on our proven ability to locate branded, generic and OTC products in all therapeutic classes and dosage forms – including the most hard-to-find medications. And, we are fully licensed for the storage and distribution of prescription medications including controlled drugs.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

ZEBLOK COMPUTATIONAL ANNOUNCES PARTNERSHIP WITH LAUFER CENTER AND CEWIT - COVID-19 DRUG DISCOVERY

Zeblok Computational, The Laufer Center, CEWIT | July 20, 2020

news image

Zeblok Computational is contributing to the efforts of two groups of researchers at The Laufer Center for Physical and Quantitative Biology, for COVID-19 drug discovery by providing Zeblok’s secure, scalable Supercomputing-as-a-Service platform, employing 128 GPUs from the CEWIT SMART GPU Cluster. The Laufer Center simulations focus on 3 key proteins of the SARS-CoV-2 virus to pinpoint more precisely which drug candidates have the best binding affinity to various protein tar...

Read More

Pharmacy Market

ASCENTAGE PHARMA ANNOUNCES ITS 9TH ORPHAN DRUG DESIGNATION FROM THE US FDA IN 2020

Ascentage Pharma | January 05, 2021

news image

Ascentage Pharma (6855.HK), an internationally engaged, clinical-stage biotechnology organization occupied with creating novel treatments for malignancies, persistent hepatitis B (CHB), and age-related sicknesses, today reported that the US Food and Drug Administration (FDA) has allowed an Orphan Drug Designation (ODD) to the organization's novel Bcl-2 inhibitor, APG-2575, for the therapy of patients with intense myeloid leukemia (AML). This is the fourth ODD allowed to APG-2575 by the US FD...

Read More

UROGEN PHARMA ANNOUNCES INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)

Business Wire | March 06, 2020

news image

UroGen Pharma Ltd. a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced the grants of inducement restricted stock units (“RSUs”) to seventy-six new employees in connection with their employment with Urogen. These new team members will support the Company as it prepares for potential approval and commercial launch of its first product candidate....

Read More

Business Insights

UCB SHOWCASES STRENGTH OF THE EXPANDING DERMATOLOGY PORTFOLIO AT THE 31ST EADV CONGRESS

UCB, Inc. | September 02, 2022

news image

UCB, a global biopharmaceutical company, today announced that it will present 20 abstracts across its dermatology portfolio at the 31st European Academy of Dermatology and Venereology (EADV) Congress in Milan, Italy, September 7-10. The abstracts, accepted for poster presentation, underscore UCB's commitment to delivering innovative solutions that aim to address the unmet needs of people living with dermatological diseases. "We are proud to present new data from our expan...

Read More
news image

ZEBLOK COMPUTATIONAL ANNOUNCES PARTNERSHIP WITH LAUFER CENTER AND CEWIT - COVID-19 DRUG DISCOVERY

Zeblok Computational, The Laufer Center, CEWIT | July 20, 2020

Zeblok Computational is contributing to the efforts of two groups of researchers at The Laufer Center for Physical and Quantitative Biology, for COVID-19 drug discovery by providing Zeblok’s secure, scalable Supercomputing-as-a-Service platform, employing 128 GPUs from the CEWIT SMART GPU Cluster. The Laufer Center simulations focus on 3 key proteins of the SARS-CoV-2 virus to pinpoint more precisely which drug candidates have the best binding affinity to various protein tar...

Read More
news image

Pharmacy Market

ASCENTAGE PHARMA ANNOUNCES ITS 9TH ORPHAN DRUG DESIGNATION FROM THE US FDA IN 2020

Ascentage Pharma | January 05, 2021

Ascentage Pharma (6855.HK), an internationally engaged, clinical-stage biotechnology organization occupied with creating novel treatments for malignancies, persistent hepatitis B (CHB), and age-related sicknesses, today reported that the US Food and Drug Administration (FDA) has allowed an Orphan Drug Designation (ODD) to the organization's novel Bcl-2 inhibitor, APG-2575, for the therapy of patients with intense myeloid leukemia (AML). This is the fourth ODD allowed to APG-2575 by the US FD...

Read More
news image

UROGEN PHARMA ANNOUNCES INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)

Business Wire | March 06, 2020

UroGen Pharma Ltd. a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced the grants of inducement restricted stock units (“RSUs”) to seventy-six new employees in connection with their employment with Urogen. These new team members will support the Company as it prepares for potential approval and commercial launch of its first product candidate....

Read More
news image

Business Insights

UCB SHOWCASES STRENGTH OF THE EXPANDING DERMATOLOGY PORTFOLIO AT THE 31ST EADV CONGRESS

UCB, Inc. | September 02, 2022

UCB, a global biopharmaceutical company, today announced that it will present 20 abstracts across its dermatology portfolio at the 31st European Academy of Dermatology and Venereology (EADV) Congress in Milan, Italy, September 7-10. The abstracts, accepted for poster presentation, underscore UCB's commitment to delivering innovative solutions that aim to address the unmet needs of people living with dermatological diseases. "We are proud to present new data from our expan...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us